PLA2G4A, phospholipase A2 group IVA, 5321

N. diseases: 202; N. variants: 15
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease 		0.080 Biomarker disease BEFREE We investigated the cellular localization of cytosolic phospholipase A(2) in the CNS following: (1) focal and global cerebral ischemia, (2) facial nerve axotomy, (3) human cases of Alzheimer's disease, (4) transgenic mice overexpressing mutant superoxide dismutase, a mouse model of amyotrophic lateral sclerosis, and (5) transgenic mice overexpressing mutant amyloid precursor protein, which exhibits age-related amyloid deposition characteristic of Alzheimer's disease. 10417811 1999
CUI: C0004114
Disease: Astrocytoma
Astrocytoma 		0.020 AlteredExpression disease BEFREE As these elements play a central role in the mechanisms of signaling involved in the activation of cytosolic phospholipase A2 (cPLA2) and cyclooxygenase-2 (COX-2), the effect of TNF-alpha on arachidonate (AA) metabolism in 1321N1 astrocytoma cells was assayed. 10501211 1999
CUI: C4086152
Disease: Childhood Astrocytoma
Childhood Astrocytoma 		0.020 AlteredExpression disease BEFREE As these elements play a central role in the mechanisms of signaling involved in the activation of cytosolic phospholipase A2 (cPLA2) and cyclooxygenase-2 (COX-2), the effect of TNF-alpha on arachidonate (AA) metabolism in 1321N1 astrocytoma cells was assayed. 10501211 1999
CUI: C0243026
Disease: Sepsis
Sepsis 		0.210 AlteredExpression disease BEFREE The significant elevation of cPLA(2) activity and expression in neutrophils during sepsis suggests that this enzyme plays a major role in neutrophil function in this clinical setting.(Blood.2000;95:660-665) 10627477 2000
CUI: C0004610
Disease: Bacteremia
Bacteremia 		0.010 AlteredExpression disease BEFREE Neutrophils from 32 septic patients with and without bacteremia were examined. cPLA(2) activity was measured using labeled phosphatidyl choline vesicles as a substrate, and total PLA(2) was determined by the release of labeled arachidonic acid from prelabeled cells. 10627477 2000
CUI: C0036690
Disease: Septicemia
Septicemia 		0.010 AlteredExpression disease BEFREE The significant elevation of cPLA(2) activity and expression in neutrophils during sepsis suggests that this enzyme plays a major role in neutrophil function in this clinical setting.(Blood.2000;95:660-665) 10627477 2000
CUI: C0004114
Disease: Astrocytoma
Astrocytoma 		0.020 AlteredExpression disease BEFREE Cytosolic phospholipase A2 and the distinct transcriptional programs of astrocytoma cells. 10838595 2000
CUI: C4086152
Disease: Childhood Astrocytoma
Childhood Astrocytoma 		0.020 AlteredExpression disease BEFREE Cytosolic phospholipase A2 and the distinct transcriptional programs of astrocytoma cells. 10838595 2000
CUI: C0035222
Disease: Respiratory Distress Syndrome, Adult
Respiratory Distress Syndrome, Adult 		0.300 Biomarker disease CTD_human Using a murine model of acute lung injury induced by septic syndrome or acid aspiration, we investigated the role of cytosolic phospholipase A2 (cPLA2) in ARDS. 10881173 2000
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.400 Biomarker disease BEFREE [1995: Med Hypotheses 45:605-613] strongly support cPLA2 (PLA2G4A) and sPLA2 (PLA2G1B) as candidate genes for schizophrenia. 11353443 2001
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.400 GeneticVariation disease BEFREE Association studies of cytosolic phospholipase A2 polymorphisms and schizophrenia among two independent family-based samples. 11807411 2001
CUI: C0003850
Disease: Arteriosclerosis
Arteriosclerosis 		0.020 Biomarker disease BEFREE The cPLA(2) thus may represent a potential therapeutic target for the control of PPAR-related liver and metabolic disorders such as obesity, lipid metabolic disorders, diabetes mellitus, and atherosclerosis. 11897617 2002
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis 		0.020 Biomarker disease BEFREE The cPLA(2) thus may represent a potential therapeutic target for the control of PPAR-related liver and metabolic disorders such as obesity, lipid metabolic disorders, diabetes mellitus, and atherosclerosis. 11897617 2002
CUI: C0028754
Disease: Obesity
Obesity 		0.020 Biomarker disease BEFREE The cPLA(2) thus may represent a potential therapeutic target for the control of PPAR-related liver and metabolic disorders such as obesity, lipid metabolic disorders, diabetes mellitus, and atherosclerosis. 11897617 2002
CUI: C0025517
Disease: Metabolic Diseases
Metabolic Diseases 		0.010 Biomarker group BEFREE The cPLA(2) thus may represent a potential therapeutic target for the control of PPAR-related liver and metabolic disorders such as obesity, lipid metabolic disorders, diabetes mellitus, and atherosclerosis. 11897617 2002
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 AlteredExpression group BEFREE We analysed the gene expression of cPLA(2) and sPLA(2)-X in 42 and 38 primary colorectal tumours, respectively, with and without K-ras mutations. 12048163 2002
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma 		0.080 AlteredExpression disease BEFREE Gene expression of cytosolic phospholipase A(2) (cPLA(2)) and protein level of secretory PLA(2) group X (sPLA(2)-X) are upregulated in human colorectal cancer and provide cyclooxygenase-2 (COX-2) with arachidonic acid, resulting in increased levels of PGE(2). 12048163 2002
CUI: C4722085
Disease: Malignant neoplasm of colon and/or rectum
Malignant neoplasm of colon and/or rectum 		0.070 AlteredExpression disease BEFREE Gene expression of cytosolic phospholipase A(2) (cPLA(2)) and protein level of secretory PLA(2) group X (sPLA(2)-X) are upregulated in human colorectal cancer and provide cyclooxygenase-2 (COX-2) with arachidonic acid, resulting in increased levels of PGE(2). 12048163 2002
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma 		0.020 AlteredExpression group LHGDN Expression of cytosolic and group X secretory phospholipase A(2) genes in human colorectal adenocarcinomas. 12048163 2002
CUI: C0022680
Disease: Polycystic Kidney Diseases
Polycystic Kidney Diseases 		0.200 Biomarker group RGD Alterations in renal cytosolic phospholipase A2 and cyclooxygenases in polycystic kidney disease. 12490538 2003
CUI: C0004623
Disease: Bacterial Infections
Bacterial Infections 		0.020 Biomarker group BEFREE The results indicate that TX production in PMNs is significantly increased through possible transcriptional mechanisms of cPLA(2) and COX-2 during bacterial infection in children. 12555215 2003
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.400 GeneticVariation disease BEFREE Our results correspond to the other studies showing an association between the cPLA2 polymorphism and schizophrenia (predominance of the A2 allele in schizophrenic subjects). 12759552 2003
CUI: C0011860
Disease: Diabetes Mellitus, Non-Insulin-Dependent
Diabetes Mellitus, Non-Insulin-Dependent 		0.010 GeneticVariation disease LHGDN PLA2G4A is located on Chromosome 1q, where a number of groups have reported linkage to type 2 diabetes mellitus. 12765847 2003
CUI: C0011860
Disease: Diabetes Mellitus, Non-Insulin-Dependent
Diabetes Mellitus, Non-Insulin-Dependent 		0.010 Biomarker disease BEFREE PLA2G4A is located on Chromosome 1q, where a number of groups have reported linkage to type 2 diabetes mellitus. 12765847 2003
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.050 Biomarker group BEFREE In addition, we identified several "pathway" genes that are rapidly emerging as novel therapeutic targets in cancer (eg, cytosolic phospholipase A2, an upstream target of the cyclooxygenase pathway, and ribosomal protein S6 kinase and eukaryotic translation initiation factor 4E, two important downstream mediators of the mitogenic Akt/mTOR signaling pathway). 12819026 2003